Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma
DOI:
https://doi.org/10.2340/actadv.v105.43240Keywords:
basal cell carcinoma, dermatology, oncology, advanced BCC, giant BCCAbstract
Cutaneous basal cell carcinoma (BCC) is a primarily indolent tumour that is easily cured. However, locally advanced BCC (laBCC) and metastatic BCC can have a poor prognosis. This retrospective cohort study, conducted at a single cancer centre over a 32-year period, reports the characteristics and clinical course of 51 patients with laBCC or metastatic BCC. Thirty-five patients were men (69%), with a mean age of 72 years. Most primary BCCs were located in the head and neck (59%), and were treated with surgery (78%). Thirty-four patients had laBCC; 6 of those developed subsequent metastasis. Twenty-three metastatic BCCs were included. The median size of laBCC was 73 mm (IQR 110; range 15–400 mm), with 71% measuring 5 cm or larger. Tumour infiltration beyond the subcutaneous fat was present in 59% of laBCC and bone infiltration in 12%. Of laBCC, 44% experienced local recurrence after resection, which was seen in 35% of local tumours later developing metastasis. Median time to metastasis was 33 months. Most patients developed nodal metastases only (70%), but 26% developed distant metastases. Fifteen patients died during follow-up (29%). Three patients died of their laBCC with a 5-year disease-specific survival of 79%. Five-year disease-specific survival for metastatic BCC was 30%. Patients with laBCC in this cohort were at high risk of local recurrence and metastasis, and 12% died of their laBCC. These findings highlight the need for intensified follow-up for this relatively rare population, especially since Hedgehog inhibitors and PD1 inhibitors might be available for these patients.
Downloads
References
Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005; 353: 2262–2269. DOI: https://doi.org/10.1056/NEJMra044151
Dutch Society for Dermatology and Venereology (NVDV). Basal Cell Carcinoma: Dutch Guideline (Dutch Society for Dermatology and Venereology (NVDV), 2015).
Work Group, Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol 2018; 78: 540–559. DOI: https://doi.org/10.1016/j.jaad.2017.10.006
Mott SE, Hunter WJ, Silva E, Huerter CJ. Approach to management of giant basal cell carcinomas. Cutis 2017; 99: 356–362. DOI: https://doi.org/10.1126/science.356.6336.362
Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, et al. Giant Basal cell carcinoma: clinico-pathological analysis of 51 cases and review of the literature. Anticancer Res 2009; 29: 2655–2663.
Maimaiti A, Mijiti A, Yarbag A, Moming A. Giant basal cell carcinoma of the face: surgical management and challenges for reconstruction. J Laryngol Otol 2016; 130: 176–182. DOI: https://doi.org/10.1017/S0022215115003333
Randle HW, Roenigk RK, Brodland DG. Giant basal cell carcinoma (T3). Who is at risk? Cancer 1993; 72: 1624–1630. DOI: https://doi.org/10.1002/1097-0142(19930901)72:5<1624::AID-CNCR2820720522>3.0.CO;2-D
Codazzi D, Bruschi S, Bocchiotti MA, Robotti E. Giant basal cell carcinoma: a series of 37 cases without metastasis. Plast Reconstr Surg 2012; 129: 999e–1000e. DOI: https://doi.org/10.1097/PRS.0b013e31824efe49
Oudit D, Pham H, Grecu T, Hodgson C, Grant ME, Rashed AA, et al. Reappraisal of giant basal cell carcinoma: Clinical features and outcomes. J Plast Reconstr Aesthet Surg 2020; 73: 53–57. DOI: https://doi.org/10.1016/j.bjps.2019.06.029
Steenrod AW, Smyth EN, Bush EN, Chang AL, Arron ST, Helfrich YR, et al. A qualitative comparison of symptoms and impact of varying stages of basal cell carcinoma. Dermatol Ther (Heidelb) 2015; 5: 183–199. DOI: https://doi.org/10.1007/s13555-015-0081-6
Laga AC, Schaefer IM, Sholl LM, French CA, Hanna J. Metastatic basal cell carcinoma molecular ancillary testing and reappraisal of histopathology within a rare entity. Am J Clin Pathol 2019; 152: 706–717.
Domarus V, Stevens PJ. Metastatic basal cell carcinoma. J Am Acad Dermatol 1984; 10: 1043–1060. DOI: https://doi.org/10.1016/S0190-9622(84)80334-5
Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24: 715–719. DOI: https://doi.org/10.1016/0190-9622(91)70108-E
Snow SN, Sahl W, Lo JS, Mohs FE, Warner T, Dekkinga JA, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994; 15; 73: 328–335. DOI: https://doi.org/10.1002/1097-0142(19940115)73:2<328::AID-CNCR2820730216>3.0.CO;2-U
Gropper AB, Girouard SD, Hojman LP, Huang SJ, Qian X, Murphy GF, et al. Metastatic basal cell carcinoma of the posterior neck: case report and review of the literature. J Cutan Pathol 2012; 39: 526–534. DOI: https://doi.org/10.1111/j.1600-0560.2012.01871.x
Kurian RR, Di Palma S, Barrett AW. Basal cell carcinoma metastatic to parotid gland. Head Neck Pathol 2014; 8: 349–353. DOI: https://doi.org/10.1007/s12105-013-0507-3
Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol 2013; 149: 615–616. DOI: https://doi.org/10.1001/jamadermatol.2013.3064
McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014; 50: 774–783. DOI: https://doi.org/10.1016/j.ejca.2013.12.013
Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J 2006; 12: 7. DOI: https://doi.org/10.5070/D313V4J8VJ
Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23: 389–402. DOI: https://doi.org/10.1023/B:CANC.0000031775.04618.30
Bourlidou E, Vahtsevanos K, Kyrgidis A, Tilaveridis I, Patsatsi A, Andreadis D, et al. Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. Eur J Dermatol 2019; 29: 490–499. DOI: https://doi.org/10.1684/ejd.2019.3643
Kokavec R, Fedeles J. Giant basal cell carcinomas: a result of neglect? Acta Chir Plast 2004; 46: 67–69.
Borel DM. Cutaneous basosquamous carcinoma: review of the literature and report of 35 cases. Arch Pathol 1973; 95: 293–297.
Montgomery H. Basal cell squamous epithelioma. Arch Dermatol Syph 1928; 18: 50–73. DOI: https://doi.org/10.1001/archderm.1928.02380130053004
Graham JH, Urbach F, Alek DS. Metastatic basal cell carcinoma. Arch Dermatol 1969; 99: 777–778.
Farmer ER, Helwig EB. Metastatic basal cell carcinoma: a clinicopathologic study of seventeen cases. Cancer 1980; 46: 748–757. DOI: https://doi.org/10.1002/1097-0142(19800815)46:4<748::AID-CNCR2820460419>3.0.CO;2-K
Laga AC, Schaefer IM, Sholl LM, French CA, Hanna J. Metastatic Basal cell carcinoma. Am J Clin Pathol 2019; 152: 706–717. DOI: https://doi.org/10.1093/ajcp/aqz089
Fecher LA. Systemic therapy for inoperable and metastatic basal cell cancer. Curr Treat Options Oncol 2013; 14: 237–248. DOI: https://doi.org/10.1007/s11864-013-0233-9
Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 2015; 27: 327–341. DOI: https://doi.org/10.1016/j.ccell.2015.02.001
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015; 16: 729–736. DOI: https://doi.org/10.1016/S1470-2045(15)70198-1
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171–2179. DOI: https://doi.org/10.1056/NEJMoa1113713
Gupta N, Ruiz ES. Current perspectives in the treatment of locally advanced basal cell carcinoma. Drug Des Devel Ther 2022; 16: 183–190. DOI: https://doi.org/10.2147/DDDT.S325852
Nahm WJ, Shen OL, Kirsner RS, Mathe CA, Nikas OV, Valadez FD, et al. Combined cryotherapy and topical imiquimod, 5-fluorouracil, and tazarotene effectively treats locally advanced basal cell carcinoma and is associated with nearby nodular basal carcinoma regression. JAAD Case Rep 2025; 58: 52–55. DOI: https://doi.org/10.1016/j.jdcr.2025.01.015
Khoo, Andre B.S., Ali, Faisal R., Lear, John T. Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice. Curr Opin Oncol 2016; 28: 180–184. DOI: https://doi.org/10.1097/CCO.0000000000000259
Richmond JD, Davie RM. The significance of incomplete excision in patients with basal cell carcinoma. Br J Plast Surg 1987; 40: 63–67. DOI: https://doi.org/10.1016/0007-1226(87)90013-0
Schmults CD, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, et al. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023; 21: 1181–1203. DOI: https://doi.org/10.6004/jnccn.2023.0056
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Anna A.J.H. Zwanenburg, Winan J. Van Houdt, A. Marjolein Schrijver, Willem H. Schreuder, Michel W. J. M. Wouters, Elsemieke I. Plasmeijer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
